Our experience in the Neo-adjuvant therapy of osteogenic sarcoma

Objective & Hypothesis:Aim: Effective adjuvant or neo-adjuvant regimens of chemotherapy have dramatically improved the prognosis of patients with high-grade osteosarcoma of the extremity, localized at diagnosis.

📊

Key Findings & Data:Methods: From Jan 1999 to Jan 2003, 15 patients with osteosarcoma of the extremity and non-metastatic at presentation, were treated according to the following scheme: primary chemotherapy with cisplatinum 100 mg/m2 day 1 at 3-week intervals and doxorubicin 25mg/m2 day 1,2,3 at 3-week intervals, resection of primary tumor and adjuvant chemotherapy. .

💡

Conclusion & Impact:Five-year event-free survival (EFS) and overall survival (OS) were 66% and 80%, respectively. 11 (73%) patients were performed limb salvage surgery.

🔬Design:Research Article

📍Scope:2003 Verileri

⚙️Variables:Kombine tedavi uygulaması · İlaç toksisitesi · Osteosarkom

Abstract

Aim: Effective adjuvant or neo-adjuvant regimens of chemotherapy have dramatically improved the prognosis of patients with high-grade osteosarcoma of the extremity, localized at diagnosis. In this study, the efficacy and tolerability of cisplatin and doxorubicin combination regimen as a neoadjuvant therapy of osteogenic sarcoma were investigated. Methods: From Jan 1999 to Jan 2003, 15 patients with osteosarcoma of the extremity and non-metastatic at presentation, were treated according to the following scheme: primary chemotherapy with cisplatinum 100 mg/m2 day 1 at 3-week intervals and doxorubicin 25mg/m2 day 1,2,3 at 3-week intervals, resection of primary tumor and adjuvant chemotherapy. . Results: Five (33%) patients achieved good response as a tumor necrosis ratio. Five-year event-free survival (EFS) and overall survival (OS) were 66% and 80%, respectively. 11 (73%) patients were performed limb salvage surgery. Neo-adjuvant chemotherapy regimen was well tolerated.Conculusion: dsplatin and doxorubicin combination regimen is considered as a reasonable option for neo-adjuvant treatment of patients with osteogenic sarcoma.

Özet

Amaç: Adjuvan veya neo-adjuvan kemoterapi rejimleri, tanı anında ekstremiteye sınırlı yüksek gradeli osteosarkom hastalarının prognozunu dramatik şekilde iyileştirmiştir. Çalışmamızda osteosarkomda neo-adjuvan olarak uygulanan sisplatin ve doksorubisin kombinasyonunun etkinliğini ve tolerabilitesini incelemek amaçlanmıştır. Yöntem: Ocak 1999 ve Ocak 2003 arasında, ekstremite yerleşimli osteosarkom tanılı 15 hasta, neo-adjuvan sisplatin 100 mg/m2 1. gün, 3 haftada bir ve doksorubisin 25 mg/mz 1., 2. ve 3. günler 3 haftada bir uygulanan kombine kemoterapi rejimi sonrası primer tümörü rezeke edilerek ve adjuvan kemoterapi uygulanarak tedavi edildi. Bulgular: 5 (%33) hastada, tümör nekroz oranlarına göre iyi cevap elde edildi. 5 yıllık hastalıksız sağ kalım %66, genel sağ kalım %80 olarak hesaptandı. 11 (%73) hastaya ekstremite koruyucu cerrahi uygulandı. Neo-adjuvan kemoterapi rejimi hastalar tarafından iyi tolere edildi. Sonuç: Sisplatin ve doksorubisin kombinasyon r&jimi, osteosarkomun neo-adjuvan tedavisinde uygun tedavi seçeneği olarak düşünülebilir.

Keywords

Kombine tedavi uygulaması İlaç toksisitesi Osteosarkom Neoadjuvant tedavi Sağkalım analizi Doksorubisin Sisplatin Combined Modality Therapy Drug Toxicity Osteosarcoma Neoadjuvant Therapy Survival Analysis Doxorubicin Cisplatin

🔖

Cite This Article

ERTEN, Ç., MEMİŞ, A., AKALIN, T., SABAH, D., YÜCETÜRK, G., KARABULUT, B., ŞANLI, U. A., GÖKER, E. (2005). Our experience in the Neo-adjuvant therapy of osteogenic sarcoma. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 15 - Sayı: 3, 187–193. https://ajindex.com/articles/268546

References (14)

Link MP, Eilber E. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and Practise of Pediatric Oncology. 3rd ed. Philadelphia: PA: Lippincott-Raven; 1997: p. 889-920
Rosen G, Forscher CA, Mankin HJ. In: Hollond JF, Frei E, editors. Cancer Medicine. 5th ed. Hamilton (ON): BC Decker; 2000: p. 1870-902
Gehan EA, Sutow WW, Uribe-Botero G. Osteosarcoma: the M.D. Anderson experience, 1950-1974. Prog Cancer Res Ther 1978;6:271-82
Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974;291:998-1000
Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973;31:1367-73
Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II study of cis-dichlorodiammine- platinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep 1979; 63:1621-7
Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985; 69:115-7
Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;19(314): 1600-6
Taylor WF, Ivins JC, Pritchard DJ, Dahlin DC, Gilchrist GS, Edmonson JH. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 1985;60:91-104
Carter SK. Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol 1984; 2:147-8
Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteo¬ sarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6
Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the ra.ionale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-24
Eilber F.C, Rosen G, Eckardt J, Forscher C, Nelson S.D, Selch M, et al. Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for highgade extremity soft tissue sarc